Abstract
Many colon cancers suffer mutations in either the adenomatous polyposis coli or beta-catenin genes that lead to stabilization of beta-catenin and activation of downstream T-cell factor (Tcf) target genes. We have developed a novel approach targeting colon cancer cells based on their aberrant beta-catenin/Tcf signaling pathway. A recombinant adenovirus, in which an apoptosis gene fadd is under the control of the promoter containing Tcf-responsive elements, selectively and efficiently kills colon cancer cells in which the beta-catenin/Tcf pathway is hyperactivated. Our data therefore provide a conceptual proof that aberrantly activated Wnt/beta-catenin/Tcf pathways can be used to selectively target colon cancers.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Apoptosis / genetics
-
Binding Sites
-
Cell Death / genetics
-
Cell Death / physiology
-
Colonic Neoplasms / genetics
-
Colonic Neoplasms / metabolism
-
Colonic Neoplasms / pathology*
-
Colonic Neoplasms / therapy
-
Cytoskeletal Proteins / genetics
-
Cytoskeletal Proteins / physiology*
-
DNA-Binding Proteins / genetics
-
DNA-Binding Proteins / physiology*
-
Genetic Therapy / methods*
-
Humans
-
Lymphoid Enhancer-Binding Factor 1
-
Promoter Regions, Genetic
-
Response Elements
-
Signal Transduction / physiology
-
Trans-Activators*
-
Transcription Factors / genetics
-
Transcription Factors / physiology*
-
Transcriptional Activation
-
Tumor Cells, Cultured
-
beta Catenin
Substances
-
CTNNB1 protein, human
-
Cytoskeletal Proteins
-
DNA-Binding Proteins
-
Lymphoid Enhancer-Binding Factor 1
-
Trans-Activators
-
Transcription Factors
-
beta Catenin